CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer.

Cell Rep Med · 2025 · PMC12047494 · PMID 40187357

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

We observed that activating KRAS-G12V mutation was associated with resistance to platinum and topoisomerase inhibitors and showed a nominally significant correlation with vemurafenib (BRAF inhibitor) ( Figures S3 B and S3C).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.